KAI Pharmaceuticals Announces Advancement of KAI-4169 Clinical Program into a ... - Business Wire (press release) PDF Print
Business Wire (press release)
Results obtained in the study will be used to select the appropriate dosing regimen for further development of KAI-4169 for the chronic management of SHPT in ESRD patients. Previous Phase 1 data demonstrated that single IV doses of KAI-4169 were safe

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.